Cargando…

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial

BACKGROUND: Use of inhaled corticosteroids (ICS) increases the risk of pneumonia in chronic obstructive pulmonary disease (COPD), but the magnitude of risk with different ICS remains unclear. METHODS: A post hoc analysis of the 4-year UPLIFT® trial to assess whether pneumonia risk differed by type o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tashkin, Donald P., Miravitlles, Marc, Celli, Bartolomé R., Metzdorf, Norbert, Mueller, Achim, Halpin, David M. G., Anzueto, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173940/ https://www.ncbi.nlm.nih.gov/pubmed/30290801 http://dx.doi.org/10.1186/s12931-018-0874-0

Ejemplares similares

Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT
por: Putcha, Nirupama, et al.
Publicado: (2022)

Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial
por: Celli, Bartolomé R., et al.
Publicado: (2016)

Impact and prevention of severe exacerbations of COPD: a review of the evidence
por: Halpin, David MG, et al.
Publicado: (2017)

Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFT(®) Trial
por: Halpin, David M. G., et al.
Publicado: (2011)

Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT(®) studies
por: Miravitlles, Marc, et al.
Publicado: (2009)

Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
por: Hanania, Nicola A, et al.
Publicado: (2011)

Adverse health consequences in COPD patients with rapid decline in FEV(1 )- evidence from the UPLIFT trial
por: Kesten, Steven, et al.
Publicado: (2011)

Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study
por: Morjaria, Jaymin B., et al.
Publicado: (2017)

Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD
por: Cazzola, Mario, et al.
Publicado: (2023)

Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial
por: Tashkin, Donald P, et al.
Publicado: (2015)

Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
por: Rabe, Klaus F., et al.
Publicado: (2020)

Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial
por: Wise, Robert, et al.
Publicado: (2015)

Exacerbation frequency and course of COPD
por: Halpin, David MG, et al.
Publicado: (2012)

Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD
por: Calverley, Peter MA, et al.
Publicado: (2018)

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study
por: Calverley, Peter MA, et al.
Publicado: (2017)

Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms
por: Avdeev, Sergey, et al.
Publicado: (2019)

Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials
por: Cooper, Christopher B, et al.
Publicado: (2011)

“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD
por: Vogelmeier, Claus, et al.
Publicado: (2017)

Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain
por: Miravitlles, Marc, et al.
Publicado: (2022)

Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial
por: Goossens, Lucas M A, et al.
Publicado: (2014)

Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease
por: Miravitlles, Marc, et al.
Publicado: (2015)

Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD
por: Tashkin, Donald P, et al.
Publicado: (2014)

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis
por: Halpin, David MG, et al.
Publicado: (2015)

Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD
por: Miravitlles, Marc, et al.
Publicado: (2021)

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
por: Brook, Robert D, et al.
Publicado: (2017)

Inhaled Corticosteroids and the Lung Microbiome in COPD
por: Keir, Holly R., et al.
Publicado: (2021)

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses
por: Halpin, David M.G., et al.
Publicado: (2018)

Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?
por: Tashkin, Donald P, et al.
Publicado: (2018)

Inhaled corticosteroids in COPD and the risk of serious pneumonia
por: Suissa, Samy, et al.
Publicado: (2013)

Inhaled corticosteroids in COPD: Personalising the therapeutic choice
por: Shaw, J A, et al.
Publicado: (2018)

How inhaled corticosteroids target inflammation in COPD
por: Lea, Simon, et al.
Publicado: (2023)

Rational use of inhaled corticosteroids for the treatment of COPD
por: Quint, Jennifer K., et al.
Publicado: (2023)

Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations
por: Calverley, Peter M, et al.
Publicado: (2016)

Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR(®) trial
por: Wise, Robert A, et al.
Publicado: (2018)

A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid
por: Miravitlles, Marc, et al.
Publicado: (2022)

Optimizing bronchodilation in the prevention of COPD exacerbations
por: Miravitlles, Marc, et al.
Publicado: (2017)

Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD
por: D’Urzo, Anthony, et al.
Publicado: (2017)

Inhaled corticosteroids and angiotensin-converting enzyme-2 in COPD
por: Lipworth, Brian, et al.
Publicado: (2021)

Time To Revise COPD Treatment Algorithm
por: Matsunaga, Kazuto, et al.
Publicado: (2019)

Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study
por: Price, David B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_53gb2b4mjqf0e6m3sltrer9o4v